Kirjallisuutta

Linkit eurooppalaiseen ja pohjoismaiseen ohjeeseen

https://www.ncbi.nlm.nih.gov/pubmed/23980065

Pohjoismainen ohje NMDSG:n kotisivuilla:

http://www.nmds.org/

Yleiskatsauksia

• Myelodysplastic syndromes. Tefferi A, Vardiman JW. N Engl J Med. 2009 Nov 5;361(19):1872-85. Review.

• Current therapeutic approaches for patients with myelodysplastic syndromes. Greenberg PL. Br J Haematol. 2010 Jul;150(2):131-43. Epub 2010 May 5. Review.

• Optimal sequencing of treatments for patients with myelodysplastic syndromes. Itzykson R, Fenaux P. Curr Opin Hematol. 2009 Mar;16(2):77-83. 
• How I treat patients with myelodysplastic syndromes. Stone RM. Blood. 2009 Jun 18;113(25):6296-303.

• Clinical management of myelodysplastic syndromes: update of SIE, SIES, GITMO practice guidelines. Santini V, Alessandrino PE, Angelucci E, Barosi G, Billio A, Di Maio M, Finelli C, Locatelli F, Marchetti M, Morra E, Musto P, Visani G, Tura S. Leuk Res. 2010 Feb 11. [Epub ahead of print]

• Pohjoismaisen MDS-työryhmän Nordic Care Programme 2014 Guideline, Issue 6

• Diagnosis and treatment of primary myelodysplastic syndromes in adults. Recommendations fron the European LeukemiaNet. Malcovati L, Hellström-Lindberg E, Bowen D, Adès L, Cermak J, Del Cañizo C, Della Porta MG, Fenaux P, Gattermann N, Germing U, Jansen JH, Mittelman M, Mufti G, Platzbecker U, Sanz GF, Selleslag D, Skov-Holm M, Stauder R, Symeonidis A, van de Loosdrecht AA, de Witte T, Cazzola M. Blood. 2013;122(17):2943-64.

• Guidelines for the diagnosis and management of adult myelodysplastic syndromes. Killick SB, Carter C, Culligan D, Dalley C, Das-Gupta E, Drummond M, Enright H, Jones GL, Kell J, Mills J, Mufti G, Parker J, Raj K, Sternberg A, Vyas P, Bowen D; British Committee for Standards in Haematology. Br J Haematol. 2014 Feb;164(4):503-25

• Myelodysplastinen oireyhtymä - monikasvoinen luuytimen toimintahäiriö. Kauppila M, Ebeling F, Kuittinen T, Pelliniemi T-T, Poikonen E, Sankelo M, Tienhaara A, Siitonen T. Suom Lääkäril 2014;35:2099-104 (http://www.fimnet.fi/cgi-cug/brs/artikkeli.cgi?docn=000041618)

• The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Arber DA, Orazi A, Hasserjian R, et al. Blood 2016;127:2391-405. (http://www.ncbi.nlm.nih.gov/pubmed/27069254)

Metylaation vähentämishoidot

• Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A, Schoch R, Gattermann N, Sanz G, List A, Gore SD, Seymour JF, Bennett JM, Byrd J, Backstrom J, Zimmerman L, McKenzie D, Beach C, Silverman LR; International Vidaza High-Risk MDS Survival Study Group. Lancet Oncol. 2009 Mar;10(3):223-32. Epub 2009 Feb 21.

• Practical recommendations for hypomethylating agent therapy of patients with myelodysplastic syndromes. Steensma DP, Stone RM. Hematol Oncol Clin North Am. 2010 Apr;24(2):389-406.

• Novel approaches for myelodysplastic syndromes: beyond hypomethylating agents. Loaiza-Bonilla A, Gore SD, Carraway HE. Curr Opin Hematol. 2010 Mar;17(2):104-9. Review.

Rautakuorma, kelaatio

• Impact of iron overload in myelodysplastic syndromes. Fenaux P, Rose C. Blood Rev. 2009 Dec;23 Suppl 1:S15-9. Review.
• Iron chelation therapy in myelodysplastic syndrome - Cui bono? Tefferi A, Stone RM. Leukemia. 2009 Aug;23(8):1373.

Immunosuppressiiviset hoidot

• Cyclosporin A therapy in hypoplastic MDS patients and certain refractory anaemias without hypoplastic bone marrow. Jonásova A, Neuwirtová R, Cermák J, Vozobulová V, Mociková K, Sisková M, Hochová I. Br J Haematol. 1998 Feb;100(2):304-9
• Antithymocyte globulin for patients with myelodysplastic syndrome. Molldrem JJ, Caples M, Mavroudis D, Plante M, Young NS, Barrett AJ. Br J Haematol. 1997 Dec;99(3):699-705.

• Antithymocyte globulin for treatment of the bone marrow failure associated with myelodysplastic syndromes. Molldrem JJ, Leifer E, Bahceci E, Saunthararajah Y, Rivera M, Dunbar C, Liu J, Nakamura R, Young NS, Barrett AJ. Ann Intern Med. 2002 Aug 6;137(3):156-63.

• Successful treatment with cyclosporin A for myelodysplastic syndrome with erythroid hypoplasia associated with T-cell receptor gene rearrangements. Shimamoto T, Iguchi T, Ando K, Katagiri T, Tauchi T, Ito Y, Yaguchi M, Miyazawa K, Kimura Y, Masuda M, Mizoguchi H, Ohyashiki K. Br J Haematol. 2001 Aug;114(2):358-61. 

• Phase II study of rabbit anti-thymocyte globulin, cyclosporine and granulocyte colony-stimulating factor in patients with aplastic anemia and myelodysplastic syndrome. Garg R, Faderl S, Garcia-Manero G, Cortes J, Koller C, Huang X, York S, Pierce S, Brandt M, Beran M, Borthakur G, Kantarjian H, Ravandi F. Leukemia. 2009 Jul;23(7):1297-302.

Lenalidomidi

• List et al. NEJM

• Practical recommendations on the use of lenalidomide in the management of myelodysplastic syndromes. Giagounidis A, Fenaux P, Mufti GJ, Muus P, Platzbecker U, Sanz G, Cripe L, Von Lilienfeld-Toal M, Wells RA. Ann Hematol. 2008 May;87(5):345-52.

• Lenalidomide on alternative days is effective in myelodysplastic syndrome with 5q- deletion. Defina M, Rondoni M, Gozzetti A, Aprile L, Chitarrelli I, Fabbri A, Lauria F, Bocchia M. Br J Haematol. 2010 Feb;148(3):483-4.

TPO-agonistit

• Thrombocytopenia in Patients With Myelodysplastic Syndromes. Jeffrey Bryan, Elias Jabbour, Hillary Prescott, Hagop Kantarjian. Semin Hematol 2010;47(3):274-280.

Muut hoidot

• Combination of 5-azacytidine and thalidomide for the treatment of myelodysplastic syndromes and acute myeloid leukemia. Raza A, Mehdi M, Mumtaz M, Ali F, Lascher S, Galili N. Cancer. 2008 Oct 1;113(7):1596-604.